𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis

✍ Scribed by Oka, Hiroshi ;Toda, Gotaro ;Ikeda, Yusei ;Hashimoto, Naoaki ;Hasumura, Yasushi ;Kamimura, Tomoteru ;Ohta, Yasuyuki ;Tsuji, Takao ;Hattori, Nobu ;Namihisa, Toshihiko ;Nishioka, Mikio ;Ito, Ken’ichi ;Sasaki, Hiroshi ;Kakumu, Shin’ichi ;Kuroki, Tetsuo ;Fujisawa, Kiyoshi ;Nakanuma, Yasuo


Book ID
105605326
Publisher
Springer-Verlag
Year
1990
Tongue
English
Weight
566 KB
Volume
25
Category
Article
ISSN
0435-1339

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


A randomized, double-blind, placebo-cont
✍ Burton Combes; Robert L. Carithers Jr.; Willis C. Maddrey; Danyu Lin; Dr Mary F. 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 792 KB

One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four strata based on entry serum bilirubin (<2 mg/dL vs. 2 mg/dL or greater) and liver histology (stages I, 1 1 vs. stages 111, IV-Ludwig criteria) were randomized within each stratum to ursodiol or placebo given in a s

The canadian multicenter double-blind ra
✍ E. Jenny Heathcote; Karen Cauch-Dudek; Valery Walker; Robert J. Bailey; Laurence 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 969 KB

Ursodeoxycholic acid, a dihydroxyl bile acid normally present in human beings in minimal amounts, becomes incorporated into the bile salt pool when taken orally. In cholestasis, bile acids are retained in the liver and are hepatotoxic. Ursodeoxycholic acid is the least-known hepatotoxic bile acid, h